Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylephrine + clonidine is a combination of two small molecule drugs, each with distinct mechanisms of action. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that acts primarily as a vasoconstrictor, increasing blood pressure and reducing nasal congestion by constricting blood vessels[2][4]. Clonidine is an alpha-2 adrenergic receptor agonist that suppresses sympathetic outflow from the central nervous system, leading to reduced heart rate and lowered blood pressure[3][5][6]. This combination may be considered in certain clinical settings where both vasoconstriction (from phenylephrine) and central sympatholytic effects (from clonidine) are desired, such as perioperative management or specific cardiovascular indications. However, their concurrent use can result in complex hemodynamic interactions; for example, clonidine increases sensitivity to phenylephrine-induced vasoconstriction[8], while phenylephrine may antagonize the antihypertensive effect of clonidine[7]. There are no widely recognized brand names or fixed-dose products containing only this combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylephrine + clonidine.